| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:09 | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma und HealthCare Royalty geben Änderung der bestehenden Lizenzvereinbarung und Beteiligung von Soleus Capital bekannt | 1.546 | EQS Group (DE) | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Bedeutende Verträge
Heidelberg Pharma und HealthCare Royalty geben Änderung der bestehenden Lizenzvereinbarung und Beteiligung von... ► Artikel lesen | |
| Fr | AtaiBeckley Inc.: AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update | 1.406 | GlobeNewswire (Europe) | Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track... ► Artikel lesen | |
| Fr | Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 808 | GlobeNewswire (Europe) | JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated... ► Artikel lesen | |
| Fr | PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights | 804 | GlobeNewswire (Europe) | Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt... ► Artikel lesen | |
| 07:33 | NurExone präsentiert seine Technologie international - Investoren blicken auf den nächsten Meilenstein | Small- & Micro Cap Investment | |||
| Fr | Day One Biopharmaceuticals, Inc.: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 619 | GlobeNewswire (Europe) | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total... ► Artikel lesen | |
| Fr | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update | 490 | GlobeNewswire (Europe) | GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| Fr | EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug | 371 | AFX News | PARIS (dpa-AFX) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19... ► Artikel lesen | |
| Fr | Servier; Day One Biopharmaceuticals: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | 335 | PR Newswire | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents... ► Artikel lesen | |
| Fr | Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet | 333 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - The biotech sector delivered a mix of regulatory milestones, strategic deals, corporate restructuring and clinical trial developments across therapeutic areas... ► Artikel lesen | |
| Fr | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.03.2026 | 300 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 06.03.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.03.2026ISIN NameDE000DG4T770 DZ... ► Artikel lesen | |
| Fr | Galapagos NV: Galapagos Creates New Subscription Right Plan | 279 | GlobeNewswire (Europe) | Mechelen, Belgium; March 6, 2026, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under... ► Artikel lesen | |
| Fr | Halozyme Therapeutics, Inc.: U.S. FDA Approves TECVAYLI in Combination with DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma | 259 | PR Newswire | FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care... ► Artikel lesen | |
| Fr | Artelo Biosciences Announces Reverse Stock Split | 240 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling... ► Artikel lesen | |
| Fr | Number of Shares and Voting Rights of ADOCIA as of February 28th, 2026 | 227 | Business Wire | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 49,800 | 2,49 | +5,00 % | 2,25 | 23.03.2026 | |
| CSL | 88,29 | 2,60 | +2,94 % | 1,84 | 10.03.2026 | |
| AMGEN | 316,00 | 8,12 | +2,57 % | 2,52 | 13.02.2026 | |
| NOVONESIS | 48,790 | 0,87 | +1,78 % | 4,25 | 20.03.2026 | |
| GENUS | 31,000 | 0,38 | +1,23 % | 0,11 | 05.03.2026 | |
| STRYKER | 314,60 | 2,98 | +0,95 % | 0,88 | 31.03.2026 | |
| BIO-TECHNE | 48,600 | 0,27 | +0,56 % | 0,08 | 13.02.2026 | |
| BRUKER | 31,600 | 0,17 | +0,54 % | 0,05 | 23.03.2026 | |
| REGENERON PHARMACEUTICALS | 652,80 | 3,02 | +0,46 % | 0,94 | 20.02.2026 | |
| SARTORIUS STEDIM BIOTECH | 166,30 | 0,69 | +0,41 % | 0,69 | 31.03.2026 |